SCHEMBL4855853

SCHEMBL4855853

c1ccc2cc(-c3nc(-c4ccc(-c5ccc(-c6c[nH]c(-c7ccc8ccccc8c7)n6)cc5)cc4)c[nH]3)ccc2c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A1 P04798 1/20 0.49
CYP1B1 Q16678 1/20 0.49
CYP1A2 P05177 3/20 0.47
ALDH1A1 P00352 2/20 0.45
SMN1; SMN2 Q16637 2/20 0.45
AR P10275 2/20 0.45
CYP11B1 P15538 2/20 0.45
CYP11B2 P19099 2/20 0.45
CYP2C9 P11712 1/20 0.45
HPGD P15428 1/20 0.45
CYP2C19 P33261 1/20 0.45
NPSR1 Q6W5P4 1/20 0.45
KDM4E B2RXH2 1/20 0.45
NPC1 O15118 1/20 0.45
MAPT P10636 1/20 0.45
NFKB1 P19838 1/20 0.45
RAB9A P51151 1/20 0.45
GFER P55789 1/20 0.45
NFKB2 Q00653 1/20 0.45
RELA Q04206 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31305440 0.95 CYP1A1 (0.56) CYP1A1CYP1B1CYP1A2ALDH1A1SMN1; SMN2
SCHEMBL5128314 0.95 CYP1A1 (0.56) CYP1A1CYP1B1CYP1A2ALDH1A1SMN1; SMN2
SCHEMBL30635827 0.90 CYP1A2 (0.48) CYP1A1CYP1B1CYP1A2ALDH1A1SMN1; SMN2
SCHEMBL27824986 0.90 CYP1A1 (0.50) CYP1A1CYP1B1CYP1A2ALDH1A1SMN1; SMN2
SCHEMBL31305475 0.89 CYP1A1 (0.53) CYP1A1CYP1B1CYP1A2ALDH1A1SMN1; SMN2
SCHEMBL2950013 0.89 CYP1A1 (0.53) CYP1A1CYP1B1CYP1A2ALDH1A1SMN1; SMN2
SCHEMBL17280243 0.89 CYP1A1 (0.49) CYP1A1CYP1B1CYP1A2ALDH1A1SMN1; SMN2
SCHEMBL26111983 0.85 CTRC (0.51) CYP1A1CYP1B1CYP1A2ALDH1A1SMN1; SMN2
SCHEMBL29662878 0.84 MAPK14 (0.53) CYP1A1CYP1B1CYP1A2ALDH1A1SMN1; SMN2
SCHEMBL17280181 0.84 MEN1 (0.43) CYP1A1CYP1B1ALDH1A1SMN1; SMN2HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7388100-B2 Tertiary amine compounds NISHIO TETSUYA 2008-06-17 US disclosed
US-20060145145-A1 Tertiary amine compounds, organic semiconductor devices using the same and organic electroluminescence devices using the same NISHIO TETSUYA 2006-07-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060145145-A1 Tertiary amine compounds, organic semiconductor devices using the same and organic electroluminescence devices using the same PIEZO1, YES1, SAT1 CYP1A1 2605/4885CYP1B1 2037/4885CYP1A2 3572/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.